 In its early launch for depression, Axsome Therapeutics, Inc.s Auvelity is already garnering robust market adoption. Demonstrating its therapeutic prowess, Auvelity also recently reported superb data for the Phase 3 ACCORD trial for Alzheimers disease agitation. 